Thromboembolic myocardial infarction after transcatheter aortic valve implantation: a spotlight on antithrombotic treatment post-TAVI

• 作者: Vasileios Kamperidis Anastasios Karlas Georgios Sianos Antonios Ziakas Haralambos Karvounis Stavros Hadjimiltiades
• 来源期刊: 老年心脏病学杂志（英文版）
• 年，卷（期）: 2021,（4）
• 所属期刊栏目: LETTER TO THE EDITOR
• 页码范围: 316-318
• 页数: 3页
• 语种: 英文

摘要

The use of dual antiplatelet therapy for the first three-six months after transcatheter aortic valve implantation (TAVI) has beensuggested.[1,2] However, the additional benefit of anticoagulant therapy during the same period has conflicting data and even the guidelines from different cardiology societies are not in line;the American College of Cardiology/American Heart Association Guidelines recommend with an indication class Ⅱb the use of vitamin K anticoagulants with an international normalized ratio (INR) of 2.5 for the first three-months post-TAVI alongside with aspirin to avoid thromboembolic events, while the European Association of Cardiology Guidelines do not[1,2] This case report presents a thromboembolic event in the coronary arteries leading to myocardial infarction and death post-TAVI, diagnosed on autopsy by identifying the thrombi on the CoreValve stent.